quinazolines has been researched along with Cholera Infantum in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (36.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, WQ; Li, YJ; Ma, WJ; Yin, YC; Zhang, BK | 1 |
| Capdevila, J; Filetti, S; Grande, E; Kreissl, MC; Newbold, K; Reinisch, W; Robert, C; Schlumberger, M; Tolstrup, LK; Zamorano, JL | 1 |
| Alcolea, V; Aparicio, J; Corbellas, M; Diaz Beveridge, R; Fonfría, M; García, J; Giménez, A; Montalar, J; Segura, Á | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Arrieta, O; Baracos, VE; De la Torre-Vallejo, M; López-Macías, D; Macedo-Pérez, EO; Orta, D; Ramírez-Tirado, LA; Sánchez-Lara, K; Turcott, J | 1 |
| Cheng, X; Cheng, Y; Kuang, Y; Pan, X; Yang, X | 1 |
| Altun, B; Cintosun, U; Tasci, I | 1 |
| Arrieta, O; Baracos, V; de la Torre-Vallejo, M; Turcott, J | 1 |
| Chatta, G; Evans, CP; Gandara, DR; Lara, PN; Longmate, J; Posadas, E; Quinn, DI; Stadler, W; Twardowski, P | 1 |
| Kim, YH; Masago, K; Mishima, M | 1 |
| Awada, A; Azim, HA; Metzger Filho, O; Saini, KS | 1 |
| Heigener, DF; Horwood, K; Mali, P; Reck, M; van Zandwijk, N; Wu, YL | 1 |
| Bass, JD; Burris, HA; Daniel, DB; Friedman, EK; Greco, FA; Hainsworth, JD; Mitchell, RB; Shipley, DL; Spigel, DR; Waterhouse, DM; Whorf, RC; Zangmeister, J | 1 |
| Awada, AH; Besse-Hammer, T; Dumez, H; Fleischer, F; Hendlisz, A; Piccart, M; Schöffski, P; Stopfer, P; Uttenreuther-Fischer, M; Wolter, P | 1 |
| Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H | 1 |
| Barthélemy, P; Daniel, C; Doubre, H; Fandi, A; Fizazi, K; Le Chevalier, T; Riviere, A; Robert, L; Ruffié, P; Viala, J | 1 |
| Hotta, K; Inoue, A; Kiura, K; Nukiwa, T; Tanimoto, M; Ueoka, H | 1 |
| Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H | 1 |
| Funk, G; Kornek, GV; Oehler, L; Scheithauer, W; Schwarz, C; Urbauer, E; Wenzel, C | 1 |
| Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J | 1 |
| Barba, MC; Barbaro, B; Boz, G; De Paoli, A; Doglietto, GB; Frattegiani, A; Gambacorta, MA; Innocente, R; Lupattelli, M; Mantini, G; Ratto, C; Rossi, C; Valentini, V; Vecchio, FM | 1 |
| Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P | 1 |
| Bach, GL; Fotiades, P | 1 |
| Pozzi, M | 1 |
| Grossi, F; Spada, S | 1 |
5 review(s) available for quinazolines and Cholera Infantum
| Article | Year |
|---|---|
Calcitonin gene‑related peptide‑mediated pharmacological effects in cardiovascular and gastrointestinal diseases (Review).
Topics: Calcitonin Gene-Related Peptide; Cardiovascular Diseases; Gastrointestinal Diseases; Gene Expression Regulation; Humans; Indole Alkaloids; Molecular Targeted Therapy; Nitroglycerin; Quinazolines; Up-Regulation | 2021 |
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Topics: Carcinoma, Neuroendocrine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Piperidines; Prognosis; Quinazolines; Risk Assessment; Thyroid Neoplasms; Treatment Outcome | 2013 |
Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2014 |
Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials.
Topics: Antineoplastic Agents; Drug Monitoring; Gastrointestinal Diseases; Humans; Incidence; Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Prevention and management of major side effects of targeted agents in breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast; Breast Neoplasms; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Skin Diseases; Trastuzumab | 2012 |
13 trial(s) available for quinazolines and Cholera Infantum
| Article | Year |
|---|---|
Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer.
Topics: Afatinib; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Nutritional Status; Quinazolines | 2015 |
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzodioxoles; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Humans; Lymphopenia; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2009 |
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Quinazolines | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Genes, erbB-1; Genes, ras; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Quinazolines; Salvage Therapy; Sorafenib; Treatment Outcome | 2011 |
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Skin Diseases; Taxoids | 2013 |
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases | 2002 |
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2003 |
Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Contraindications; Cystitis; Feasibility Studies; Female; Gastrointestinal Diseases; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonia; Quinazolines; Vomiting | 2005 |
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome | 2006 |
Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diarrhea; Drug Tolerance; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Infusions, Intravenous; Male; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms; Safety | 2008 |
[Treatment of rheumatoid arthritis with biarison. Results of a double-blind study with placebo (author's transl)].
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Evaluation; Drug Tolerance; Female; Gastrointestinal Diseases; Humans; Male; Placebos; Quinazolines | 1978 |
[Clinical trials of an association of a choleretic (1-morpholinoacetyl-3-phenyl-4-oxo-1,2,3,4-tetrahydroquinazoline hydrochloride), (Rec 14-0127) and phenolphthalein and belladonna extract].
Topics: Atropa belladonna; Cholagogues and Choleretics; Clinical Trials as Topic; Gastrointestinal Diseases; Humans; Liver Diseases; Morpholines; Phenolphthaleins; Phytotherapy; Placebos; Plants, Medicinal; Plants, Toxic; Quinazolines; Tuberculosis, Pulmonary | 1969 |
7 other study(ies) available for quinazolines and Cholera Infantum
| Article | Year |
|---|---|
Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Drug Evaluation; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2014 |
Sarcopenia Is a Condition With Increasing Importance in Medical Oncology.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Quinazolines | 2016 |
In Reply.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Quinazolines | 2016 |
Erlotinib and gastrointestinal ulcer.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Humans; Male; Peptic Ulcer; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonoscopy; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Enterocolitis; Fatal Outcome; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2006 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2001 |
[Pharmacological and clinical aspects of the use of a new choleretic, 1-morpholinoacetyl-3-phenyl-4-oxo-1,2,3,4-tetrahydroquinazoline hydrochloride].
Topics: Adult; Bile; Biliary Tract Diseases; Cholagogues and Choleretics; Feces; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Quinazolines | 1969 |